New York, Jan 16, 2026, 20:21 EST — Market closed.
- Pfizer shares slipped 0.9% on Friday, closing at $25.65.
- U.S. stock markets will be closed Monday in observance of Martin Luther King Jr. Day; trading picks up again on Tuesday.
- Pfizer’s ex-dividend date on Jan. 23 and its quarterly earnings report due Feb. 3 are in investors’ sights.
Pfizer shares slipped 0.9% to close at $25.65 on Friday, just ahead of the U.S. market’s long weekend. Trading volume hit roughly 58 million shares. (MarketScreener)
The tape will be silent Monday as U.S. exchanges shut down for Martin Luther King Jr. Day. Trading resumes Tuesday’s regular session. (New York Stock Exchange)
Pfizer faces a packed schedule of catalysts in the coming weeks as it works to reverse a lengthy slide in its stock. In December, the company projected adjusted 2026 earnings of $2.80 to $3.00 per share on revenues between $59.5 billion and $62.5 billion. It also warned of about a $1.5 billion decline in COVID-19 product sales, alongside another $1.5 billion hit from patent expirations and ensuing generic competition. “This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said. (Reuters)
Friday’s trading was quiet for U.S. stocks. The S&P 500 edged down 0.06%, while the Dow dropped 0.17%. Most large drug companies lost ground, though Gilead bucked the trend with gains. (MarketWatch)
Friday brought a Pfizer-linked story that reflected the biotech sector’s tone more than Pfizer’s own quarterly results. Agomab Therapeutics, backed by Pfizer, filed for a U.S. IPO, revealing a bigger loss. Reuters noted Pfizer participated in Agomab’s Series B funding and remains a key shareholder as the IPO approaches. (Reuters)
This matters on the margins since Pfizer has relied on deals to rejuvenate its pipeline, and investors quickly penalize anything lacking near-term growth or obvious margin improvement.
That said, the setup could easily snap the other way. If cautious remarks about 2026 demand for Pfizer’s COVID treatments resurface, or if patent expirations hit harder than anticipated, the stock could stay stuck—or even slide further down.
Investors chasing income should note Pfizer’s upcoming dividend: $0.43 per share. The ex-dividend date falls on Jan. 23, with payments scheduled for March 6, according to Pfizer’s investor relations page. (Pfizer Investors)
Pfizer is set to release its fourth-quarter 2025 earnings and hold its quarterly corporate performance webcast on Feb. 3 at 10:00 a.m. ET. (Pfizer Investors)
Traders are watching closely for any adjustments, up or down, to the 2026 forecasts, along with how management addresses cost control and the speed of replacement growth. Pfizer’s stock faces its next clear, date-fixed test on Feb. 3.
